key: cord-0968847-m3zgxr0u authors: Mukherjee, Rukmini; Bhattacharya, Anshu; Bojkova, Denisa; Mehdipour, Ahmad Reza; Shin, Donghyuk; Khan, Khadija Shahed; Hei-Yin Cheung, Hayley; Wong, Kam-Bo; Ng, WaiLung; Cinatl, Jindrich; Geurink, Paul P.; van der Heden van Noort, Gerbrand J.; Rajalingam, Krishnaraj; Ciesek, Sandra; Hummer, Gerhard; Dikic, Ivan title: Famotidine inhibits Toll-like receptor 3-mediated inflammatory signaling in SARS-CoV2 infection date: 2021-06-30 journal: J Biol Chem DOI: 10.1016/j.jbc.2021.100925 sha: 411a19f24fe34fa97ad23c46e42fa3172fa471a5 doc_id: 968847 cord_uid: m3zgxr0u Apart from prevention using vaccinations, the management options for COVID-19 remain limited. In retrospective cohort studies, use of famotidine, a specific oral H2 receptor antagonist (antihistamine), has been associated with reduced risk of intubation and death in patients hospitalized with COVID-19. In a case series, non-hospitalized patients with COVID-19 experienced rapid symptom resolution after taking famotidine, but the molecular basis of these observations remains elusive. Here we show using biochemical, cellular, and functional assays that famotidine has no effect on viral replication or viral protease activity. However, famotidine can affect histamine-induced signaling processes in infected Caco2 cells. Specifically, famotidine treatment inhibits histamine-induced expression of Toll-like receptor 3 (TLR3) in SARS-CoV-2 infected cells and can reduce TLR3-dependent signaling processes that culminate in activation of IRF3 and the NF-κB pathway, subsequently controlling anti-viral and inflammatory responses. SARS-CoV-2-infected cells treated with famotidine demonstrate reduced expression levels of the inflammatory mediators CCL-2 and IL6, drivers of the cytokine release syndrome that precipitates poor outcome for patients with COVID-19. Given that pharmacokinetic studies indicate that famotidine can reach concentrations in blood that suffice to antagonize histamine H2 receptors expressed in mast cells, neutrophils, and eosinophils these observations explain how famotidine may contribute to the reduced histamine-induced inflammation and cytokine release, thereby improving the outcome for patients with COVID-19. The COVID-19 pandemic caused by the (12, 13, 14) . dsRNA virus activated MCs also trigger innate immune signaling through TLR3, which causes activation of IRF3 and synthesis of interferons (11) . TLR3 mediated signaling is an important anti-viral signaling pathway that is activated in coronavirus infections (15) . In humans, the TLR family comprises ten members In silico docking studies show two potential binding sites in SARS-CoV-2 Since several studies suggested that SARS- (18, 19) . Famotidine has no effect on the main protease (3CLpro) or on viral replication. Several reports suggest that the anti-viral effect of Famotidine on patients is due to inhibition of the coronavirus main protease inhibiting CPE (Fig. 2b) . Since Famotidine is an H2 receptor antagonist, we assumed that the beneficial effects of cells also showed an increase in ISG15 and CCL2, which was reduced in cells pretreated with Famotidine (Fig. 5d ). To confirm that the effect of Famotidine on the TBK1/IRF3 pathway is through TLR3 dependent signaling we treated Caco2 cells with the TLR3 inhibitor CU-CPT 4a, which was added at the time of infection. TBK1 and IRF3 phosphorylation is unaffected by histamine and Famotidine when TLR3 signaling is inhibited by CU-CPT 4a (Fig. 6a ). Also, ISG15 and CCL2 levels are lower in the presence of the inhibitor and is unaffected by Famotidine treatment (Fig. 6b) . Therefore, at the molecular level Famotidine has cellular, not viral targets that influence, e.g., the histamine-induced expression of TLR3 and, in turn, mediates innate immune signaling through the IRF3 and NF-κB pathway (Fig. 6c ). and SARS-CoV were cloned into pET28b for bacterial expression as described before (19) . For mammalian expression, PLpros were cloned into pEGFP-C1 (clontech). SARS-CoV-2 PLPro and SARS-CoV PLpro were purified from Escherichia coli as described before (19) . The expression and purification of 3CLpro protein and protein substrate protein were performed as described previously (29, 30) . The sequence of SARS-CoV-2 3CLpro was obtained from GenBank (accession number: YP_009725301), codon-optimized, and ordered from GenScript. A C-terminal poly-histidine-maltose binding protein (His6-MBP) tag with two in-between Factor Xa digestion sites were inserted. The recombinant protein substrate His6 -CFP -TSAVLQ↓SGFRKM -YFP (where ↓ represent the cleavage site) was constructed, expressed and purified as described (31, 32) . As docking target, we used the structural model of SARS-CoV-2 PLpro with bound GRL-067 in our previous simulation study (19, Boceprevir and 5% DMSO were served as positive control and negative control, respectively (22) . The reduction of fluorescence at 530 nm was fitted to a single exponential decay to obtain the observed rate constant (kobs) using GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA). Relative activity of 3CLpro was defined as the ratio of kobs with inhibitors to that without. The relative inhibition concentration (IC50) value of Famotidine was determined by fitting the relative activity at different inhibitor concentration to a four-parameter logistics equation. Virus was prepared as described before (19) . SARS-CoV-2 strain FFM1 (accession no. using Caco-2 cells. Virus titres were determined as TCID50 per ml in confluent cells in 96-well microtitre plates. Caco2 cells were pretreated with 100µM histamine and 50µM Famotidine for 12h followed by Peptides were subjected to TMT labelling with 1:2 peptide TMT ratio (w/w) for1 h at room temperature. The labelling reaction was quenched by addition of hydroxylamine to a final concentration of 0.5% and incubation at room temperature for an additional 15 min. Samples were pooled in equimolar ratio, and subjected to High pH Reversed-Phase Peptide Fractionation kit (ThermoFisher Scientific) following the manufacturer's instructions. Eluted fractions were dried in SpeedVac and peptides were resuspended in 3% acetonitrile/ 0.1% TFA for liquid chromatography-mass spectrometry. All mass spectrometry data was acquired in centroid mode on an Orbitrap Fusion Lumos mass spectrometer hyphenated to an easy-nLC 1200 nano HPLC system with a nanoFlex ion source (ThermoFisher Scientific). Resuspend peptides were separated on an Easy nLC 1200 (ThermoFisher Scientific) and a 22-cm-long, 75-μminnerdiameter fused-silica column, which had been packed in house with 1.9-μm C18 particles (ReproSil-Pur, Dr. Maisch), and kept at 45 °C using an integrated column oven (Sonation). Peptides were eluted by a nonlinear gradient from 8-60% acetonitrile over 155 min followed by an increase to 95%B in 1 minute which was held for another 10 minutes. Full-scan MS spectra Cells were lysed using lysis buffer (50mM Tris (pH:7.5), 150mM NaCl, 1% Triton-X-100) for cellular assays and Virus infected cells were lysed in hot SDS-lysis buffer (50mM Tris, 2% SDS, 10mM TCEP, 40mM chloroacetamide, protease inhibitor cocktail). 20µg protein was loaded in 10% Tris-glycine gel which was run at 150V for 1.5h, followed by transfer to PVDF membrane for 2h,300mA, and immunoblotted with antibodies. We used the following antibodies and dilutions for this study: To analyse the induction of IFN-β induced genes and NF-κB genes, a luciferase reporter assay was used in A549 cells. In brief, an expression construct containing the luciferase ORF and the IFN-β promoter (IFN-β-luciferase) or NF-κB promoter was transfected.100ng plasmid was used The mass spectrometry data used in our study has been submitted to the ProteomeXchange Consortium and Famotidine (50µM,12h) were lysed in Trizol, followed by RNA isolation and RT-PCR using TLR specific primers. Error bars indicate s.d, p** p<0.01 (c)TLR3 dependent signaling was assayed after virus infection using indicated antibodies. (d) CCL2 and ISG15 mRNA levels were measured by RT-PCR using RNA used in panel (b). Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study Impact of Famotidine use on clinical outcomes of hospitalized patients with COVID-19 Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalised patients: a case series Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Profiling SARS-CoV-2 Main Protease (MPRO) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural NetworkTrained Force Fields The Effect of Famotidine on SARS-CoV-2 proteases and virus replication Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy COVID-19: Famotidine, histamine, mast cells Potential Association of Mast Cells with COVID-19 Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies An inflammatory cytokine signature predicts COVID-19 severity and survival SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection The potential danger of suboptimal antibody responses in COVID-19 Toll-like receptors and COVID-19: a two-faced story with an exciting ending A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity Recognition of Lys48linked di-ubiquitin and deubiquitinating activities of the SARS coronavirus papain-like protease Class AG protein-coupled receptor antagonist Famotidine as a therapeutic alternative against SARS-CoV2: an in silico analysis SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Mechanism of SARS-CoV-2 polymerase stalling by remdesivir Modulation of expression and function of Toll-like receptor 3 in A549 and H292 cells by histamine Modulation of mast cell toll-like receptor 3 expression and cytokines release by histamine Physiological implications of biased signaling at histamine H2 receptors Insulin-dependent phosphatidylinositol 3-kinase/Akt and ERK signaling pathways inhibit TLR3mediated human bronchial epithelial cell apoptosis Profiling of substrate specificity of SARS-CoV 3CLpro Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronvirus 3C-like proteases Metascape provides a biologist-oriented resource for the analysis of systems-level datasets We would like to thank S Mathea for his help with the DSF assay, Marina Hoffmann for mass spectrometry and D. Hoeller and A. Gubas for critical reading. The authors declare no conflict of interest.